Outlook Therapeutics Raises $10M in Stock Offering

TL;DR

OTLK just sold $10M in stock, closing soon. Need cash for operations.

AI Summary

Outlook Therapeutics, Inc. announced on April 15, 2024, that it entered into a securities purchase agreement for the sale of approximately $10.0 million of its common stock in a registered direct offering. The company expects to close this offering on or about April 17, 2024. This offering is part of the company's ongoing efforts to secure financing for its operations.

Why It Matters

This capital raise provides Outlook Therapeutics with crucial funding, potentially enabling them to advance their drug development pipeline or cover operational expenses.

Risk Assessment

Risk Level: medium — The company is raising capital through a stock offering, which can dilute existing shareholders and indicates a need for funds, suggesting potential financial pressures.

Key Numbers

• $10.0M — Registered Direct Offering (Funds raised to support operations)

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — Registrant
• April 15, 2024 (date) — Date of Report
• $10.0 million (dollar_amount) — Amount of securities purchase agreement
• April 17, 2024 (date) — Expected closing date of offering

FAQ

Key Financial Figures

• $0.01 — f the Company's common stock, par value $0.01 per share (the "Common Stock"), and, fo
• $7.00 — he "Securities") at a purchase price of $7.00 per Share and accompanying Warrant to p
• $7.70 — The Warrants have an exercise price of $7.70 per share of Common Stock and will expi

Filing Documents

• tm2411870d1_8k.htm (8-K) — 22KB
• 0001104659-24-047322.txt ( ) — 193KB
• otlk-20240415.xsd (EX-101.SCH) — 3KB
• otlk-20240415_lab.xml (EX-101.LAB) — 33KB
• otlk-20240415_pre.xml (EX-101.PRE) — 22KB
• tm2411870d1_8k_htm.xml (XML) — 4KB

02 Unregistered Sales of Equity

Item 3.02 Unregistered Sales of Equity Securities. On April 15, 2024, Outlook Therapeutics, Inc. (the "Company") closed its previously announced private placement (the "Private Placement") to Syntone Ventures LLC ("Syntone") of shares of the Company's common stock, par value $0.01 per share (the "Common Stock"), and, for each share of Common Stock issued in the Private Placement (each, a "Share"), accompanying warrants to purchase up to one and a half shares of Common Stock (the "Warrants" and, together with the Shares, the "Securities") at a purchase price of $7.00 per Share and accompanying Warrant to purchase one and a half shares of Common Stock. At the Closing, the Company issued an aggregate of 714,286 Shares and Warrants to purchase an aggregate of 1,071,429 shares of Common Stock. The Warrants have an exercise price of $7.70 per share of Common Stock and will expire on April 15, 2029. The Shares and Warrants were sold and, upon exercise the shares of Common Stock underlying the Warrants, will be issued without registration under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and/or Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. Syntone made relevant representations in the securities purchase agreement with respect to the Private Placement. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of common stock or other securities of the Company.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: April 15, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR